Ravi Madan

Ravi Madan: Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing

Ravi Madan, Clinical researcher focused on Prostate Cancer at National Cancer Institute, shared a post on X:  .

“Now online. European Urology Oncology: Enzalutamide Monotherapy in EMBARK BCR Prostate Cancer Should Be Practice-changing, and Existing Data Suggest How to Mitigate Toxicity.”

Visit the article website.
Source: Ravi Madan/X

Ravi Madan: Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing

BCR cancer EMBARK Enzalutamide European Urology Oncology National Cancer Institute NCI OncoDaily Oncology prostate cancer Ravi Madan Research